Drug Trial Radar · NCT05670730
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping
Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Nov 9, 2022
Primary completion
Nov 25, 2024
Study completion Nov 25, 2024
Sponsor
- Lead sponsor
- Avidity Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 7 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping. Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers. Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.
Conditions
- Duchenne Muscular Dystrophy
- Exon 44
Interventions
AOC 1044Drug
AOC 1044 will be administered via intravenous (IV) infusion
PlaceboDrug
Placebo will be administered via intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, up to Day 85 (Part A) or Day 169 (Part B)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's
Little Rock, Arkansas
UCSD
La Jolla, California
Stanford University
Palo Alto, California
Rare Disease Research - Atlanta
Atlanta, Georgia
University of Iowa
Iowa City, Iowa
University of Massachusetts Chan Medical School
Worcester, Massachusetts
Gillette Children's
Saint Paul, Minnesota
Rare Disease Research NC
Hillsborough, North Carolina
Abigail Research Institute at Nationwide Children's Hospital
Columbus, Ohio
Worldwide Clinical Trials (Part A only)
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.